Showing 1241-1250 of 1511 results for "".
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- Johnson & Johnson Vision Expands “Sight For Kids” Program and Unveils “Vision for Good” Community Impact Reporthttps://modernod.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/Johnson & Johnson Vision announced the expansion of nonprofit program
- Johnson & Johnson Vision Announces FDA Approval of Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Abiliti-Overnight Therapeutic Lenses. This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia. “The FDA approval of Abiliti Overnight marks an
- Johnson & Johnson Vision Announces FDA Approval Of Tecnis Synergy And Tecnis Synergy Toric II IOLs In the UShttps://modernod.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/Johnson & Johnson Vision announced the FDA approval of Tecnis Synergy and Tecnis Synergy Toric II IOLs, and the Health Canada approval of Tecnis Synergy Toric II IOLs. This next-generation PCIOL is built on the legacy Tecnis platform and delivers a wide range of continuous vision with
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Johnson & Johnson Vision Receives Approval in Canada for First Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-first-drug-releasing-contact-lens-for-vision-correction-and-allergic-eye-itch/2479117/Johnson & Johnson Vision received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: Acuvue Theravision with Ketotifen.1 The lens contains an H1 hista
- Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/Johnson & Johnson Vision announced the FDA 510(k) clearance and CE mark of its next-generation phacoemulsification device, the Veritas Vision System. The phaco system features technologies that allow surgeons to guide through any lens density with less surge and more stability. The new system
- Johnson & Johnson Vision Introduces Acuvue Abiliti to Address Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-abiliti-to-address-myopia-in-children/2479101/Johnson & Johnson Vision announced the launch of Acuvue Abiliti, a new brand for future products and services aimed at helping parents and eye care providers address the growing prevalence and progression of myopia in children. Abiliti will provide parents and eye care providers with c
- Feds Call Halt to Johnson & Johnson COVID-19 Vaccine Rollout After ‘Extremely Rare’ Blood Clot Caseshttps://modernod.com/news/feds-call-halt-to-johnson-johnson-covid-19-vaccine-rollout-after-extremely-rare-blood-clot-cases/2479070/After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials are calling fo
- Johnson & Johnson Takes Charge of Emergent COVID-19 Vaccine Manufacturing Sitehttps://modernod.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/The US Department of Health & Human Services (HHS) has put Johnson & Johnson in charge of the Emergent BioSolutions’ Bayview facility in Baltimore, which ruined around 15 million doses of its COVID-19 vaccine Ad26.COV2.S. Johnson & Johnson said it was “assuming full